Table Graph
      published meta-analysis   sensitivity analysis   studies

standard of care in COVID 19 all comers - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLou (FAVIPIRAVIR), 2020 (REV) 0.89 [0.02; 50.23] 0.89[0.02; 50.23]Lou (FAVIPIRAVIR), 2020 (REV)10%19NAnot evaluable clinical improvementdetailed resultsLou (FAVIPIRAVIR), 2020 (REV) 0.80 [0.13; 4.87] 0.80[0.13; 4.87]Lou (FAVIPIRAVIR), 2020 (REV)10%19NAnot evaluable clinical improvement (14-day)detailed resultsLou (FAVIPIRAVIR), 2020 (REV) 0.80 [0.13; 4.87] 0.80[0.13; 4.87]Lou (FAVIPIRAVIR), 2020 (REV)10%19NAnot evaluable viral clearance detailed resultsLou (FAVIPIRAVIR), 2020 (REV) 5.43 [0.21; 139.89] 5.43[0.21; 139.89]Lou (FAVIPIRAVIR), 2020 (REV)10%19NAnot evaluable viral clearance by day 14detailed resultsLou (FAVIPIRAVIR), 2020 (REV) 5.43 [0.21; 139.89] 5.43[0.21; 139.89]Lou (FAVIPIRAVIR), 2020 (REV)10%19NAnot evaluable ICU admissiondetailed resultsLou (FAVIPIRAVIR), 2020 (REV) 0.18 [0.01; 4.75] 0.18[0.01; 4.75]Lou (FAVIPIRAVIR), 2020 (REV)10%19NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-07-01 19:20 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 94 - treatments: 651 - roots T: 651

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons